Risvodetinib Demonstrates Disease-Modifying Biomarker Reversal in Parkinson's Disease Phase 2 Trial
Key Insights
ABLi Therapeutics (search) completed an exhaustive biomarker study of risvodetinib encompassing 7,300 individual measures from up to 80 participants in the Phase 2 201 Trial.
All three doses (50, 100, 200 mg) inhibited c-Abl kinase (search) and suppressed neuroinflammation, with 100 and 200 mg doses substantially reducing phosphorylated alpha-synuclein (search) in spinal fluid and blood.
The 12-week once-daily oral treatment demonstrated consistent reversal of the biological cascade underlying Parkinson's disease (search) pathology in both central and peripheral nervous systems.
ATLANTA and BOSTON — ABLi Therapeutics (search) announced on August 4, 2026, the completion of an exhaustive biomarker study from its Phase 2 201 Trial, revealing that its investigational therapy risvodetinib substantially reversed key pathological markers of Parkinson's disease (search) across tissue, blood, and cerebrospinal fluid samples. The analysis, encompassing 7,300 individual measures from up to 80 participants, provides what the company describes as a portrait of how disease modification "should look" in human Parkinson's disease.
"The analysis of tissue, blood and spinal fluid measures from participants in the 201 Trial has revealed surprising information, both about the underlying processes of disease and how patients respond to risvodetinib treatment," said Dr. Milton Werner, ABLi's Chairman and Chief Executive. "The outcomes indicate that the biological cascade of disease is reflected by these biomarkers and is substantially reversed in 12-weeks of once daily treatment with risvodetinib, including substantial reduction in phosphorylated alpha-synuclein (search), believed to be the causative agent of human PD."
Biomarker Analysis Across Multiple Pathways
ABLi launched in May 2025 following initial demonstration of drug-related reductions in alpha-synuclein (search) aggregates in skin biopsy samples from 36 participants. The company subsequently expanded its biomarker evaluation, adding longitudinal blood measures from 80 participants and cerebrospinal fluid measures from 6 participants, with samples collected at baseline and at the conclusion of the 12-week trial. In total, 11 markers were analyzed, reporting on processes of neuronal degeneration, mitochondrial health, and neuroinflammation.
The analysis yielded three principal findings. First, all three tested doses — 50 mg, 100 mg, and 200 mg administered once daily — successfully inhibited the target c-Abl kinase (search). Second, the 100 mg and 200 mg doses substantially reduced phosphorylated alpha-synuclein (search) biomarkers in spinal fluid, while all three doses substantially reduced phosphorylated alpha-synuclein levels in blood. Third, all three doses suppressed neuroinflammation, as measured by suppression of NLRP3 (search) and the pro-inflammatory cytokines IL-1beta and IL-18, to levels below baseline.
Clinical Implications and Next Steps
Based on these results, ABLi has identified the 100 mg and 200 mg once-daily doses for further evaluation in its upcoming BASE, ABILITY, and CAMPD trials. The company is also exploring diagnostic and prognostic applications of these biomarkers to inform the late-stage CAMPD trial, which will examine correlations between markers of disease biology and clinical outcomes.
Risvodetinib is a potent, selective small-molecule inhibitor of non-receptor c-Abl kinases, designed for once-daily oral administration. It targets the underlying biological mechanisms believed to drive Parkinson's disease (search) initiation and progression. Currently, all marketed therapies for Parkinson's disease manage symptoms only, with no available treatments to slow or stop disease progression. Risvodetinib was previously the first monotherapy shown to improve patient quality of life in a randomized, placebo-controlled clinical trial (NCT05424276) while simultaneously reducing underlying synuclein aggregate pathology in untreated Parkinson's disease.
ABLi stated that these and other new data will be the subject of an upcoming meeting with the FDA in August 2026. Risvodetinib currently holds intellectual property protection beyond 2036.